filmov
tv
What the FDA feedback means for Antisense Therapeutics
Показать описание
Antisense Therapeutics has received formal written feedback from the US Food and Drug Administration (FDA) on its development plans for ATL1102 for non-ambulant patients with Duchenne muscular dystrophy (DMD).
Non- Executive Director Charmaine Gittleson discusses the implications.
Non- Executive Director Charmaine Gittleson discusses the implications.